I-SPY2 TRIAL Demonstrates Significant Improvement in pCR with Durvalumab and Olaparib with Paclitaxel\, (Compared to Chemotherapy Alone) in Women with Stage II/III High-Risk\, HER2-Negative Breast Cancer\, in HR+ and TNBC Subsets